Tokyo, Japan – [June 24, 2025] — AMS is pleased to announce that our Chief Technology Officer, Dr. Komei Washino, has co-authored a research article that has been published in the prestigious journal Annals of Nuclear Medicine.

The paper, titled “Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma,” presents key preclinical findings critical to the safe advancement of targeted alpha therapy using 211At-labeled compounds.

This study addresses the acute toxicity profile of [211At]meta-astatobenzylguanidine (211At-MABG), an alpha-emitting radiopharmaceutical being developed for the treatment of rare neuroendocrine tumors—pheochromocytoma and paraganglioma. The results pave the way for upcoming first-in-human clinical trials, representing a significant milestone in the development of novel, precision-targeted alpha therapies for difficult-to-treat cancers.

“We are proud that Dr. Washino’s contributions to this groundbreaking research have been recognized in one of the field’s leading journals,” said Yuichiro Sugawara, CEO of AMS “This work exemplifies our commitment to advancing science and innovation at the interface of nuclear medicine and oncology.”

The article is now available online in Annals of Nuclear Medicine: https://link.springer.com/article/10.1007/s12149-025-02065-0.